Insights

Despite Granting a Request for Rehearing, the PTAB Maintained Its Finding that Teva’s Copaxone Claims Were Unpatentable as Obvious, <i>PTAB Litigation Blog</i>

Despite Granting a Request for Rehearing, the PTAB Maintained Its Finding that Teva’s Copaxone Claims Were Unpatentable as Obvious, PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB granted-in-part Patent Owner Teva’s request for rehearing of the Final Written Decisions finding every claim of the challenged patents obvious over the prior art.  In granting rehearing in part, the PTAB vacated its original decisions and concurrently entered modified Final Written Decisions maintaining that the challenged claims are unpatentable as obvious over the prior art.

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.